Professor Paul Kalra
Queen Alexandra Hospital, Portsmouth (United Kingdom of Great Britain & Northern Ireland)
Ferric derisomaltose in heart failure with iron deficiency - an update from the IRONMAN trial
Event: Heart Failure 2024
Topic: Anaemia/Iron Deficiency
Session: Trials of IV iron: what we got right and what we didn’t. How can the new ESC guidelines help improving clinical practice?
IRONMAN: anaemia, iron deficiency and quality of life in heart failure and its response to IV iron
Event: Heart Failure 2023
Topic: Pharmacotherapy
Session: Late breaking clinical trials
IRONMAN
Event: Heart Failure 2023
Topic: Heart Failure Association (HFA)
Session: HF clinical trials of 2022
IV iron improves morbidity and (perhaps) mortality
Event: Heart Failure 2023
Topic: Chronic Heart Failure
Session: IV iron: the story so far
Infection risk with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency: a prespecified analysis of the IRONMAN trial
Event: Heart Failure 2023
Topic: Comorbidities
Session: Chronic heart failure - clinical
IRONMAN in perspective
Event: Heart Failure 2023
Topic: Chronic Heart Failure
Session: Iron deficiency: where are we?
What's in the IV iron trial pipeline and what will it add?
Event: Heart Failure 2021
Topic: Treatment
Session: Iron deficiency and heart failure - evidence is piling up - what's next?
Current guidelines and what on-going RCTs could do to change them.
Event: Heart Failure 2020
Topic: Pharmacotherapy
Session: IV Iron in heart failure: what we know and what we don't.
Iron supplementation: how, when and in which patients.
Event: HFA Webinar
Topic: Epidemiology, Prognosis, Outcome
Session: HFA Webinars 2020
Opening and setting the scene ; Current knowledge and knowledge gaps. What questions will ongoing CVOTs address? Discussion/Questions and Answers.
Event: HFA Discoveries
Topic: Pharmacotherapy
Session: IV iron in heart failure – what we know and what we don’t
ESC 365 is supported by
